Amsterdam

• FORE-PAIN trial Recruiting
  2022-500176-63-00 5 2025-05-20 Acute traumatic pain
• A Phase 2, Open-label, Randomized Study to Evaluate Prophylactic Interventions on Talquetamab-related Oral Toxicity Recruiting
  2023-506260-14-00 4 2025-05-13 multiple myeloma
• A Study of Duvelisib Versus the Anti-cancer Drugs Gemcitabine or Bendamustine in Patients With T Cell lymphoma (a type of blood cancer), whi … Recruiting
  2024-516605-23-00 5 2025-05-12 relapsed/refractory nodal T cell lymphoma with T follicular helper (TF
• Ravulizumab dose optimization Recruiting
  2024-519207-10-00 6 2025-05-12 Paroxysmal nocturnal hemoglobinuria (PNH)
• A Phase 3, multicenter, open label, randomized, non-comparative two-arm study of ivosidenib monotherapy (IVO) and azacitidine monotherapy (A … Recruiting
  2023-510155-37-00 5 2025-05-08 Hypomethylating agent (HMA) naive myelodysplastic syndromes Myelodyspl
• A trial to learn how well baxdrostat with dapagliflozin works compared to dapagliflozin on clinical outcomes alone and how safe it is in adu … Recruiting
  2023-506460-14-00 5 2025-05-07 Chronic kidney disease (CKD) and hypertension.
• A study to evaluate the benefit of adding durvalumab after chemotherapy, durvalumab and surgery in patients with early-stage, operable, non- … Recruiting
  2023-508773-82-00 5 2025-05-06 Stage IIB-IIIB (N2) resectable non small cell lung cancer
• Towards organ preservation and cure via immunotherapy in cutaneous squamous cell carcinoma patients, normally undergoing morbid curative sur … Recruiting
  2024-516152-17-00 4 2025-04-24 Cutaneous squamous cell carcinoma
• A Phase 3 Study of a GPRC5D-directed CAR T Cell Therapy in Participants with Relapsed or Refractory Multiple Myeloma and Exposed to Lenalido … Recruiting
  2024-515279-37-00 5 2025-04-17 Relapsed or Refractory and Lenalidomide exposed Multiple Myeloma
• A Study to Test the Effectiveness and Safety of RO7790121 for induction and maintenance therapy in Patients with Moderately to Severely Acti … Recruiting
  2024-513053-69-00 5 2025-04-16 Moderately to Severely Active Crohn's Disease (CD)
• Transtympanic sodium thiosulfate to prevent cisplatin-related hearing loss, a randomized controlled multicenter phase III trial; The SOUND t … Recruiting
  2023-503313-30-01 5 2025-04-14 Head and Neck squamous cell carcinoma
• StAtins in Frail oldEr patients with ischemic Stroke or Transient ischemic attack – The Randomized Controlled Trial Recruiting
  2024-517343-31-00 6 2025-04-11 Ischemic stroke and transient ischemic attack
• Treatment of ELectroencephalographic STatus epilepticus After cardiopulmonary Resuscitation-2 (TELSTAR-2): a multicenter randomised clinical … Recruiting
  2024-516068-27-01 5 2025-04-10 status epilepticus
• First-in-human Trial of DS-2243a in Participants with Advanced Solid Tumors Recruiting
  2024-512058-11-00 1 2025-04-09 Advanced Solid Tumor
• Exploiting the synergistic effect of PARP inhibition with cisplatin and hyperthermia during interval cytoreductive surgery and HIPEC in ovar … Recruiting
  2024-519170-39-00 9 2025-04-07 fallopian tube cancer
• FARE Trial Recruiting
  2023-506594-35-00 6 2025-03-24 Rectal cancer
• Metal Panel Patch Test Recruiting
  2023-507972-35-01 5 2025-03-24 Allergic contact dermatitis
• 68-Ga-FAPI-46 positron emission tomography (PET) to better visualise pancreatic and bile duct cancer. Recruiting
  2024-516486-36-00 10 2025-03-24 cholangiocarcinoma (bile duct cancer)
• PRESERVE-003: ONC-392 (Study Drug) Versus Docetaxel (Standard of Care) in Metastatic Non-small Cell Lung Cancer That Progressed on PD-1/PD-L … Recruiting
  2023-505311-20-01 5 2025-03-21 Metastatic Non-Small Cell Lung Cancer
• Biodistribution Evaluation to Reduce Administered Radiopharmaceutical Dose on LOng Axial Field of VieW PET Scanners – BELOW trial Recruiting
  2024-512906-24-00 3 2025-03-21 Cancer
• MEtformin as a MEtabolic iNTervention in Oesophageal adenocarcinomas to improve response to neoadjuvant chemoradiotherapy Recruiting
  2024-511626-30-00 4 2025-03-09 Oesophageal adenocarcinoma
• CD8 PET imaging in metastatic solid tumours; A phase II, open label, multi-center study of 89Zr-DF-crefmirlimab for CD8 positron emission to … Recruiting
  2024-515885-15-00 9 2025-03-04 Patients with metastatic solid tumours, where clinical data has shown
• Whole body HER3 quantification with radiolabelled Patritumab deruxtecan (HER3-DXd) PET/CT Recruiting
  2023-508233-14-00 4 2025-03-03 EGFR mutation positive advanced stage NSCLC
• A clinical trial to learn about the safety and effects of VERT-002, a new anticancer drug for the treatment of patients with advanced solid … Recruiting
  2024-512760-64-00 7 2025-02-26 locally advanced or metastatic solid tumors with MET alterations

Showing 361–384 of 1,127 trials